Compare BioNTech SE - ADR (BNTX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs KB Financial Group, Inc. — how do they compare? BioNTech SE - ADR trades at $90.03 (market cap $22.86B), while KB Financial Group, Inc. trades at $121.09 (market cap $41.53B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays a 2.6% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KB | |
|---|---|---|
Market Cap | $22.86B | $41.53B |
Sector | Health | Financials |
52-Week High | $119.34 | $123.25 |
52-Week Low | $83.89 | $77.50 |
Enterprise Value | $6.53B | — |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
KB Financial Group (KB) trades at $123.25, up 0.05% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, 27.82% net income margin, and 27.47% profit margin in 2025. Recent news highlights expansion into non-banking segments and dividend potential. Revenue grew to $21.23T in 2025, with net income reaching $5.83T.
The outlook remains positive with earnings growth and diversification driving upside, though technical oscillators signal overbought conditions. Risks include volatile cash flows and competitive pressures. Analyst consensus is mixed with 33% buy ratings. The stock presents value with a P/E of 11.84 but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
